Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer.
Open access · bronzeAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 62 citations in OpenAlex.
- Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma.The oncologist · 2021Trial
- Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer.Clinical breast cancer · 2018Trial
- Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Trial
- Platelet-Related Signature in Colorectal Cancer: Prognosis and Therapy Guidance.International journal of molecular sciences · 2026Article
- Slap restricts oncogenic Src-family kinase signaling to maintain colonic epithelial homeostasis.eLife · 2026Article
- Identification of Drug-resistant Cell Subpopulations in Colorectal Cancer Through Single-cell Analysis and Exploration of Potential Therapeutic Strategies.Current medicinal chemistry · 2026Article
- Berberine: a promising strategy to combat cetuximab-resistance in colorectal cancer.BMC cancer · 2025Article
- Progastrin Promotes Colorectal Cancer Stem Cell-Like Properties via the Receptor PZR.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Transcriptomic signatures and network-based methods uncover new senescent cell anti-apoptotic pathways and senolytics.The FEBS journal · 2025Article
- Focal adhesion in the tumour metastasis: from molecular mechanisms to therapeutic targets.Biomarker research · 2025Review
- Synergistic Mechanisms of Selected Polyphenols in Overcoming Chemoresistance and Enhancing Chemosensitivity in Colorectal Cancer.Antioxidants (Basel, Switzerland) · 2024Review
- Molecular perspectives on systemic priming and concomitant immunity in colorectal carcinoma.Journal of the Egyptian National Cancer Institute · 2024Review
- Dasatinib suppresses collective cell migration through the coordination of focal adhesion andHeliyon · 2024Article
- Role of c-Src in Carcinogenesis and Drug Resistance.Cancers · 2023Review
- DDX52 gene expression in LUAD tissues indicates potential as a prognostic biomarker and therapeutic target.Scientific reports · 2023Article
- Targeted Therapies in Colorectal Cancer: Recent Advances in Biomarkers, Landmark Trials, and Future Perspectives.Cancers · 2023Review
- A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFNature cancer · 2023Article
- Immune Pathways with Aging Characteristics Improve Immunotherapy Benefits and Drug Prediction in Human Cancer.Cancers · 2023Article
- ML216-Induced BLM Helicase Inhibition Sensitizes PCa Cells to the DNA-Crosslinking Agent Cisplatin.Molecules (Basel, Switzerland) · 2022Article
- Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6.Cancer research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 3 countries.
Christine M ParseghianDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. cparseghian@mdanderson.org.
Nila U ParikhDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ji Yuan WuDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Zhi-Qin JiangDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Laura HendersonDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Feng TianDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Brice PastorIRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France.
Marc YchouIRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France.
Kanwal RaghavDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Arvind DasariDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
David R FogelmanDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Anastasia D KatsiampouraDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
David G MenterDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Robert A WolffDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cathy EngDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Michael J OvermanDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Alain R ThierryIRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France.
Gary E GallickDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Scott KopetzDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
The University of Texas MD Anderson Cancer Center · USInstitut de Recherche en Cancérologie de Montpellier · FRThe University of Texas Medical Branch at Galveston · USTsinghua University · CN
Funding
Center for Clinical and Translational Sciences (CCTS)KL2TR000370 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$4.3MTumor Heterogeneity and Acquired Resistance to EGFR InhibitionR01CA184843 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HAMILTON, STANLEY R., KOPETZ, SCOTT · 2015 to 2019
$3.2MStress Signaling Pathways and Resistance in Colorectal CancerR01CA172670 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOPETZ, SCOTT · 2013 to 2017
$1.6MNCATS NIH HHS KL2 TR000370NCI NIH HHS R01 CA172670NCI NIH HHS R01 CA184843
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAntineoplastic Combined Chemotherapy ProtocolsCetuximabColorectal NeoplasmsCSK Tyrosine-Protein KinaseDasatinibDisease-Free SurvivalErbB ReceptorsFemaleFluorouracilHumansLeucovorinMaleMaximum Tolerated DoseMiddle AgedCetuximabCSK protein, humanCSK Tyrosine-Protein KinaseDasatinibEGFR protein, humanErbB ReceptorsFluorouracilKRAS protein, humanLeucovorinOrganoplatinum CompoundsProto-Oncogene Proteins p21(ras)src-Family Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.